We are constantly seeking participants for a number of studies. Please apply to any studies for which you may qualify, or call us at (417) 883-7889 for more information!
This study is an episodic migraine study for ages 18-75 using a neuromodulator device on your upper arm. This device will sync via Bluetooth to a smartphone, which will control the device, as well as the location of headache diary. A total of up to 4 visits spanning no longer than 4 months with a 1-month baseline period, 1-month placebo-controlled period, and an optional 2-month open-label period.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of investigational medication for the Acute Treatment of Episodic Migraine in Adolescents. Qualified patients ages 12-17 will attend up to 3 visits and treat up to 2 migraines over 28 weeks with study medication.
This research study is to compare the duration, safety, and effectiveness of the investigational study medication (Fremanezumab) to placebo (an inactive look-alike). Qualified volunteers will be randomly assigned to receive study medication or placebo. Completion of the study would involve coming to our office for 7 appointments, over a 44-week period. Subjects will receive 3 doses of investigational product or placebo during the study.
The study is for subjects 18 and older. The study duration is up to 3 years. Subject will receive both oral study drug once daily and subcutaneous study drug every other week. Period 1 is 56 weeks and 13 site visits. Subject will have a site visit at week 56 and every 12 weeks thereafter.
The research study is available for participants 18 and older. The subject will take the study drug once daily. There are 13 office visits in Period 1. The study duration is up to 3 years. Subject will have a study visit at week 56 and every 12 weeks thereafter.
Clinvest Research is currently enrolling participants for a phase 3 clinical study investigating a new selective JAK1 inhibitor for Rheumatoid Arthritis. Participants need to be over 18 years of age, have diagnosis of Rheumatoid Arthritis, have had an inadequate response or intolerant to previous treatments, and on a stable dose of a Synthetic Disease Modifying Anti-Rheumatic Drug. The study is up to 5 years in duration. Compensation for time and travel may be provided and study related care is at no cost.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine.